Intervention not reported
Progression‐free survival### · patients with multiple myeloma
The intervention showed no clear difference in progression‐free survival### (low certainty).
1 finding from 1 review
Intervention not reported
Vertebral fractures · patients with multiple myeloma
The intervention probably leads to lower vertebral fractures (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐vertebral fractures · patients with multiple myeloma
The intervention showed no clear difference in non‐vertebral fractures (moderate certainty).
1 finding from 1 review
Intervention not reported
Skeletal‐related events · patients with multiple myeloma
The intervention probably leads to lower skeletal‐related events (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain · patients with multiple myeloma
It is very uncertain whether the intervention changes pain (very low certainty).
1 finding from 1 review
Intervention not reported
Osteonecrosis of jaw · patients with multiple myeloma
The intervention showed no clear difference in osteonecrosis of jaw (low certainty).
1 finding from 1 review
Maximal inspiratory pressure (cmH2O) Postintervention for insp. training at 10 weeks, for exp. training after 2‐3 months · people with multiple sclerosis
1 finding from 1 review
Maximal expiratory pressure (cmH2O) Postintervention for insp. training at 10 weeks, for exp. training after 2‐3 months · people with multiple sclerosis
1 finding from 1 review
Predicted maximal inspiratory pressure (%) Postintervention after 10 weeks · people with multiple sclerosis
1 finding from 1 review
Predicted maximal expiratory pressure (%) Postintervention after 10 weeks · people with multiple sclerosis
1 finding from 1 review
Quality of Life (EQ‐5D VAS, score · people with multiple sclerosis
1 finding from 1 review
Fatigue · people with multiple sclerosis
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg probably leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Mean Expanded Disability Status Scale score change from baseline · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Number of participants whose disability worsened · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review